DrugPatentWatch Database Preview

XURIDEN Drug Profile

« Back to Dashboard

When do Xuriden patents expire, and when can generic versions of Xuriden launch?

Xuriden is a drug marketed by Wellstat Therap and is included in one NDA. There is one patent protecting this drug.

This drug has one hundred and seventy-five patent family members in twenty-one countries.

The generic ingredient in XURIDEN is uridine triacetate. There are thirty-five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the uridine triacetate profile page.

Summary for XURIDEN

International Patents:	175
US Patents:	1
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	50
Patent Applications:	38
Formulation / Manufacturing:	see details
Drug Prices:	see details
DailyMed Link:	XURIDEN at DailyMed

Pharmacology for XURIDEN

Ingredient-type	Pyrimidines Analogs/Derivatives
Drug Class	Pyrimidine Analog

Synonyms for XURIDEN

(2R,3R,4R,5R)-2-(ACETOXYMETHYL)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)TETRAHYDROFURAN-3,4-DIYL DIACETATE

[(2R,3R,4R,5R)-3,4-diacetoxy-5-(2,4-dioxopyrimidin-1-yl)tetrahydrofuran-2-yl]methyl acetate

[(2R,3R,4R,5R)-3,4-diacetyloxy-5-(2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl acetate

105T388

2 ,3 ,5 -Triacetyluridine

2',3',5'-Tri-O-acetyluridine

293738-13-3

2WP61F175M

4105-38-8

AC1L2FGB

AK-73070

AKOS015964563

AN-158

ANW-29551

API0001026

AUFUWRKPQLGTGF-FMKGYKFTSA-N

AX8007900

CHEBI:90914

CHEMBL2107381

CTK3J5861

D09985

D0OL7F

DB09144

EINECS 223-881-5

FT-0081134

J-700012

KSC495Q6D

MFCD00023795

MLS006009982

MolPort-005-940-324

NU000494

PN 401

PN401

PubChem14176

RG 2133

SCHEMBL871011

SMR004701034

SY004945

Tri-O-acetyluridine

Triacetyluridine

UNII-2WP61F175M

URI007

Uridine 2',3',5'-triacetate

Uridine triacetate

Uridine triacetate (USAN/INN)

Uridine triacetate [USAN:INN]

Uridine, 2',3',5'-triacetate

Vistonuridine

Xuriden (TN)

ZINC3843198

US Patents and Regulatory Information for XURIDEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wellstat Therap	XURIDEN	uridine triacetate	GRANULE;ORAL	208169-001	Sep 4, 2015		RX	Yes	Yes			Y
Wellstat Therap	XURIDEN	uridine triacetate	GRANULE;ORAL	208169-001	Sep 4, 2015		RX	Yes	Yes
Wellstat Therap	XURIDEN	uridine triacetate	GRANULE;ORAL	208169-001	Sep 4, 2015		RX	Yes	Yes

Non-Orange Book US Patents for XURIDEN

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
7,166,581	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
7,105,498	Acylated uridine and cytidine and uses thereof
6,020,322	Acyl deoxyribonucleoside derivatives and uses thereof
5,968,914	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides

International Patents for XURIDEN

Country	Document Number	Estimated Expiration
Japan	2003160585
Germany	69232070
European Patent Office	0771204
Hong Kong	1003425

Supplementary Protection Certificates for XURIDEN

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2017 00036	Denmark		PRODUCT NAME: TRIFLURIDINE IN COMBINATION WITH TIPIRACIL OR A PHARMACEUTICALLY ACCEPTABLE SALT OF TIPIRACIL; REG. NO/DATE: EU/1/16/1096 20160427
0889	Netherlands		PRODUCT NAME: TRIFLURIDINE IN COMBINATIE MET TIPIRACILHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/16/1096 20160427